MET and lung cancer: The current study screened and characterized the clinicopathological features of MET exon 14 skipping mutations, gene amplification and protein overexpression using a cohort of resectable lung cancers in Taiwan, and identified two exon 14 skipping mutations (both derived from c3208G>C mutation), three gene amplifications and 14 protein overexpressions.